reported that the positivity of PD-L1 from 75% to 37.5% after neoadjuvant chemotherapy in NSCLC (18), while Rojkó revealed that PD-L1 expression showed no significant changes after neoadjuvant chemotherapy in patients with lung cancer (25). This evidence concerns the gene CD274 and non-small cell lung carcinoma.